Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas |
| December 06, 2020 | December 2020 Bond Updates |
|
EAST HANOVER, N.J., Dec. 5, 2020 /PRNewswire/ -- Novartis announced analyses from two separate trials with Kymriah® (tisagenlecleucel) in patients with certain advanced lymphomas. In the interim analysis of the investigational Phase II ELARA study, Kymriah led to a complete response (CR)... |
| View more at: https://www.prnewswire.com:443/news-releases/novartis-analyses-confirm-benefit-of-kymriah-with-clinically-meaningful-rates-of-complete-response-seen-in-patients-with-certain-advanced-lymphomas-301186828.html |
| Related News |